---

Video features

---

Dr. Ryan discusses her approach to treating patients and how Dana-Farber's scientific advancements help develop new clinical therapies for lymphoma.

---

​At ASH22, Dr. Davids details a study in high-risk CLL that found a triplet regimen AVO was highly effective, with a 86% rate of undetectable minimual residual disease​

---

​


​In an interview with the Patient Empowerment Network, Dr. Davids details each type of treatment options available for patients with CLL

---

​


​Dr. Chrisitine Ryan's interview with CLL Society’s Director of Scientific Affairs and Research, Robyn Brumble, RN, MSN

---

​
​Dr. Davids being interviewed on NESN RED SOX Final at Fenway Park for the 17th annual WEEI/NESN Jimmy Fund Radio-Telethon

---

​

Check out Dr. Davids talking about his work treating patients with CLL, Hodgkin's and non-Hodgkin's lymphoma at DFCI

---